| Market Capitalization (Millions $) |
5 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
4 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-3 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Titan Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative treatments for medical disorders. Based in South San Francisco, California, the company focuses primarily on the development of therapeutics for central nervous system (CNS) disorders and conditions. Titan Pharmaceuticals is known for its expertise in the field of long-term, continuous drug delivery, utilizing its proprietary ProNeura technology platform.
The company has successfully developed and commercialized Probuphine, an implantable buprenorphine-based treatment for opioid addiction. Probuphine is designed to provide a constant, low-level release of medication for six months, eliminating the need for daily dosing and reducing the risk of non-compliance.
In addition to opioid addiction, Titan Pharmaceuticals is actively researching and developing treatments for other CNS disorders, including Parkinson's disease and hypothyroidism. The company has ongoing collaborations with various academic institutions and pharmaceutical partners to advance its research and development pipelines.
Overall, Titan Pharmaceuticals Inc. is dedicated to developing innovative therapies with an emphasis on long-term and continuous drug delivery, aiming to improve patients' quality of life and simplify treatment regimens for various medical conditions.
Company Address: 10 East 53rd St. New York 10022 NY
Company Phone Number: 244-4990 Stock Exchange / Ticker: NASDAQ TTNP
|
5.55%